Physician profile

Steven Mcgrath

Pain Medicine · Cherry Hill, NJ

NPI 1992091888

$4,838.00

in general payments reported to CMS, 2019-2025

41 companies · $597 in 2025

The $597 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).

See the full distribution for Pain Medicine

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,062.33

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Scilex Pharmaceuticals INC. $714.16 2019-2025 Ztlido
Collegium Pharmaceutical, INC. $621.36 2019-2025 Belbuca, Xtampza
Abbott Laboratories $518.07 2019-2025 Proclaim, Octrode
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $411.91 2019-2025 Relistor
Vertos Medical, INC. $234.58 2019-2024 Mild Device Kit
Medtronic, INC. $219.72 2024-2025 Intellis Adaptivestim, Accurian
Si-Bone, INC. $217.26 2021-2025
Boston Scientific Corporation $211.10 2019-2024 Wavewriter Alpha Prime 16
Pfizer INC. $203.46 2019-2025
Nevro Corp. $171.26 2020-2024 Senza
Kowa Pharmaceuticals America, INC. $102.70 2022-2023 Seglentis, Livalo
Horizon Therapeutics Plc $100.18 2019-2022
Biodelivery Sciences International, INC. $92.44 2019-2021
Protega Pharmaceutials INC $79.15 2022-2024 Roxybond
Spr Therapeutics, INC $73.64 2024-2025 Sprint Pns System
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Ibsa Pharma INC. $71.52 2021-2025 Tirosint, Licart, Tirosint
Redhill Biopharma INC. $67.54 2020-2021
Zyla Life Sciences, INC. $67.39 2019-2020
Daiichi Sankyo INC. $63.49 2019
Valinor Pharma, LLC $47.47 2023-2025 Movantik
Mdd US Operations, LLC $47.19 2019-2020
Almatica Pharma LLC $41.11 2022-2023 Gralise
Teva Pharmaceuticals USA, INC. $40.30 2022-2023 Ajovy
West Therapeutics Development, LLC $36.98 2019
Uswm, LLC $36.49 2021-2022
Shionogi INC $35.93 2019
Pacira Therapeutics, INC. $34.94 2019-2020
International Rehabilitative Sciences, INC $32.56 2023-2024 Rs 4i Plus Sequential Stimulator
Biohaven Pharmaceutical Holding Company LTD. $28.28 2022
Grt US Holding, INC. $28.13 2020-2021
Sanofi-Aventis U.S. LLC $26.37 2019-2022
Arbor Pharmaceuticals, INC. $23.23 2019-2020
Stimwave Technologies Incorporated $22.40 2019
Medtronic USA, INC. $16.99 2019
Abbvie INC. $16.57 2023
Biohaven Pharmaceuticals, INC. $14.92 2021
Azurity Pharmaceuticals, INC. $14.57 2023 Horizant
Vertex Pharmaceuticals Incorporated $14.17 2025
Pacira Pharmaceuticals Incorporated $13.55 2023 Iovera, Zilretta
Hikma Pharmaceuticals USA $12.54 2021
Assertio Therapeutics, INC. $12.38 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven Mcgrath

$4,838.00

in general payments reported 2019-2025

Years
2019-2025
Top company
Scilex Pharmaceuticals INC.
Context
The $597 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).

https://glasscript.com/doctor/790146/steven-mcgrath

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.